Nimish Patel1, David Huang2, Thomas Lodise3,4. 1. Pharmacy Practice, Albany College of Pharmacy and Health Sciences, 106 New Scotland Ave, Albany, NY, 12208-3492, USA. 2. Motif BioSciences, Inc., 125 Park Avenue, 25th Floor, New York, NY, 10017, USA. 3. Pharmacy Practice, Albany College of Pharmacy and Health Sciences, 106 New Scotland Ave, Albany, NY, 12208-3492, USA. thomas.lodise@acphs.edu. 4. IDRx Solutions LLC, 11 Mohagany Drive, Albany, NY, 12208, USA. thomas.lodise@acphs.edu.
Abstract
BACKGROUND AND OBJECTIVE: Vancomycin is the most prescribed antibiotic for hospitalized adults with skin and skin structure infections. Vancomycin is associated with acute kidney injury. Iclaprim is an antibiotic under development for the treatment of patients with acute bacterial skin and skin structure infections and is not associated with acute kidney injury. This economic model sought to determine the potential cost saving with iclaprim owing to avoidance of vancomycin-associated acute kidney injury among hospitalized patients with acute bacterial skin and skin structure infections. MATERIALS AND METHODS: A hospital cost-minimization model was developed to estimate the overall cost impact of replacing empiric vancomycin with iclaprim among hospitalized adult patients with skin and skin structure infections. The structural model included: vancomycin acquisition; vancomycin assay; incidence of vancomycin-associated acute kidney injury; excess hospital length of stay if acute kidney injury occurred; frequency/cost of specialty physician consults after occurrence of acute kidney injury; and probability/cost of acute dialysis as a result of acute kidney injury. Iclaprim treatment duration was 7 days and iclaprim acquisition cost was varied to determine the upper end of the daily iclaprim price that still conferred cost savings relative to vancomycin. Duration of hospitalization for iclaprim was assumed to be the same as patients with no acute kidney injury. RESULTS: Based on the overall acute kidney injury rate (9.2%), the neutral acquisition price threshold for iclaprim vs. vancomycin was US$1373.47/regimen. Across various subpopulations where acute kidney injury risk ranged between 9.2 and 16.7%, the daily iclaprim acquisition cost that still conferred cost savings was up to US$300/day. CONCLUSIONS: Iclaprim has the potential to reduce the economic burden of acute bacterial skin and skin structure infections in hospitalized patients at risk for vancomycin-associated acute kidney injury when iclaprim acquisition is US$300/day or less.
BACKGROUND AND OBJECTIVE:Vancomycin is the most prescribed antibiotic for hospitalized adults with skin and skin structure infections. Vancomycin is associated with acute kidney injury. Iclaprim is an antibiotic under development for the treatment of patients with acute bacterial skin and skin structure infections and is not associated with acute kidney injury. This economic model sought to determine the potential cost saving with iclaprim owing to avoidance of vancomycin-associated acute kidney injury among hospitalized patients with acute bacterial skin and skin structure infections. MATERIALS AND METHODS: A hospital cost-minimization model was developed to estimate the overall cost impact of replacing empiric vancomycin with iclaprim among hospitalized adult patients with skin and skin structure infections. The structural model included: vancomycin acquisition; vancomycin assay; incidence of vancomycin-associated acute kidney injury; excess hospital length of stay if acute kidney injury occurred; frequency/cost of specialty physician consults after occurrence of acute kidney injury; and probability/cost of acute dialysis as a result of acute kidney injury. Iclaprim treatment duration was 7 days and iclaprim acquisition cost was varied to determine the upper end of the daily iclaprim price that still conferred cost savings relative to vancomycin. Duration of hospitalization for iclaprim was assumed to be the same as patients with no acute kidney injury. RESULTS: Based on the overall acute kidney injury rate (9.2%), the neutral acquisition price threshold for iclaprim vs. vancomycin was US$1373.47/regimen. Across various subpopulations where acute kidney injury risk ranged between 9.2 and 16.7%, the daily iclaprim acquisition cost that still conferred cost savings was up to US$300/day. CONCLUSIONS: Iclaprim has the potential to reduce the economic burden of acute bacterial skin and skin structure infections in hospitalized patients at risk for vancomycin-associated acute kidney injury when iclaprim acquisition is US$300/day or less.
Authors: Lindsey Pritchard; Catherine Baker; James Leggett; Paul Sehdev; Allen Brown; K Bruce Bayley Journal: Am J Med Date: 2010-12 Impact factor: 4.965
Authors: Thomas P Lodise; Nimish Patel; Ben M Lomaestro; Keith A Rodvold; George L Drusano Journal: Clin Infect Dis Date: 2009-08-15 Impact factor: 9.079
Authors: Keith S Kaye; Dipen A Patel; Jennifer M Stephens; Alexandra Khachatryan; Ayush Patel; Kenneth Johnson Journal: PLoS One Date: 2015-11-24 Impact factor: 3.240
Authors: Nimish Patel; Nicholas Stornelli; Ryan J Sangiovanni; David B Huang; Thomas P Lodise Journal: Antimicrob Agents Chemother Date: 2020-09-21 Impact factor: 5.191
Authors: Selina K Jorch; Bas Gj Surewaard; Mokarram Hossain; Moritz Peiseler; Carsten Deppermann; Jennifer Deng; Ania Bogoslowski; Fardau van der Wal; Abdelwahab Omri; Michael J Hickey; Paul Kubes Journal: J Clin Invest Date: 2019-11-01 Impact factor: 14.808
Authors: Marc H Scheetz; Thomas P Lodise; Kevin J Downes; George Drusano; Michael Neely Journal: J Antimicrob Chemother Date: 2021-06-18 Impact factor: 5.790